EMA Withdrawn: Zenapax (daclizumab) — Roche Registration Ltd.

View source ↗

Summary

EMA has withdrawn Zenapax (daclizumab) from the market in January 2007.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft Rejection
• Kidney Transplantation

Drugs mentioned

• Zenapax (daclizumab)

Snippet

Status: Withdrawn. Therapeutic area: Graft Rejection;Kidney Transplantation. MAH: Roche Registration Ltd.. Decision date: 23/01/2007